

6.2 ANTIMICROBIAL STEWARDSHIP



ANTIMICROBIAL STEWARDSHIP

| Intervention Type | 2 nd Q 2022 | 3 rd Q 2022 | 4 th Q 2022 | 1 st Q 2023 | 12 Month Total |
|-------------------------|------------------------|------------------------|------------------------|------------------------|----------------|
| De-escalation | 249 | 306 | 321 | 350 | 1,226 |
| Dose adjustment | 2,425 | 2,705 | 2,979 | 3,123 | 11,232 |
| Bug-Drug mismatch | 91 | 85 | 97 | 121 | 394 |
| IV to PO conversion | 420 | 280 | 336 | 488 | 1,524 |
| Therapeutic duplication | 62 | 70 | 73 | 138 | 343 |
| Totals | 3,247 | 3,446 | 3,806 | 4,220 | 14,719 |

ANTIMICROBIAL STEWARDSHIP

2023

Lab - New Vitek Cards Forthcoming to include updated CLSI standards for MICs

Implementation of Disease State Specific PowerPlans to Align with Joint Commission Standards: UTI and SSTI

Optimization of Procalcitonin Laboratory based reporting

Surgical Site Infection Interdisciplinary Process Improvement Team-Updated Antibiotic Guidance

Standardization of Restriction Process for Antimicrobials - Ceftaroline

Updated Broward Health's Renal Dosing Policy which includes antimicrobials

Formulary Removal – Ciprofloxacin IV/PO, Prevnar-13, Lindane Shampoo

Formulary Additions – Bexsero Vaccine, Nitazoxanide

Updated Post-Splenectomy PowerPlan

Pneumococcal Vaccination Formulary Streamlining based on new CDC recommendations

Antibiogram Update

Continual Evaluation of Utilization of Restricted Antimicrobials